Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome |
| |
| Authors: | B. Vergès A. Avignon F. Bonnet B. Catargi S. Cattan E. Cosson G. Ducrocq M. Elbaz A. Fredenrich P. Gourdy P. Henry O. Lairez A.M. Leguerrier C. Monpère P. Moulin B. Vergès-Patois R. Roussel G. Steg P. Valensi |
| |
| Affiliation: | 1. Service d’endocrinologie, diabétologie et maladies métaboliques, hôpital du Bocage, CHU, 21000 Dijon, France;2. Service des maladies métaboliques, CHU de Montpellier, 34000 Montpellier, France;3. Service d’endocrinologie, diabétologie et nutrition, CHU de Rennes, 35000 Rennes, France;4. Service d’endocrinologie, CHU de Bordeaux, 33000 Bordeaux, France;5. Service de cardiologie, CHI de Le Raincy-Montfermeil, 93370 Le Raincy-Montfermeil, France;6. Service d’endocrinologie, diabétologie et nutrition, CHU Jean-Verdier, 93140 Bondy, France;7. Service de cardiologie, CHU Bichat, 75018 Paris, France;8. Service de cardiologie, CHU de Toulouse, 31059 Toulouse, France;9. Service de diabétologie-endocrinologie, CHU de Nice, 06002 Nice, France;10. Service de diabétologie, maladies métaboliques, nutrition, CHU de Toulouse, 31059 Toulouse, France;11. Service de cardiologie, CHU Lariboisière, 75010 Paris, France;12. Service de réadaptation cardiaque, 37510 Bois-Gibert, France;13. Service d’endocrinologie et maladies de la nutrition, hôpital cardiologique Louis-Pradel, CHU de Lyon, 69677 Bron, France;14. Service de réadaptation cardiaque, Les Rosiers, 21000 Dijon, France;15. Service de diabetologie-endocrinologie et nutrition, CHU Bichat, 75018 Paris, France |
| |
| Abstract: | The Diabetes and Cardiovascular Disease study group of the Société francophone du diabète (SFD, French Society of Diabetes) in collaboration with the Société française de cardiologie (SFC, French Society of Cardiology) have devised a consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome (ACS); in particular, it includes the different phases of ACS [the intensive care unit (ICU) period, the post-ICU period and the short-term follow-up period after discharge, including cardiac rehabilitation] and also embraces all of the various diagnostic and therapeutic issues with a view to optimalizing the collaboration between cardiologists and diabetologists. As regards diagnosis, subjects with HbA1c greater or equal to 6.5% on admission may be considered diabetic while, in those with no known diabetes and HbA1c less than 6.5%, it is recommended that an OGTT be performed 7 to 28 days after ACS. During hospitalization in the ICU, continuous insulin treatment should be initiated in all patients when admission blood glucose levels are greater or equal to 180 mg/dL (10.0 mmol/L) and, in those with previously known diabetes, when preprandial glucose levels are greater or equal to 140 mg/dL (7.77 mmol/L) during follow-up. The recommended blood glucose target is 140–180 mg/dL (7.7–10 mmol/L) for most patients. Following the ICU period, insulin treatment is not mandatory for every patient, and other antidiabetic treatments may be considered, with the choice of optimal treatment depending on the metabolic profile of the patient. Patients should be referred to a diabetologist before discharge from hospital in cases of unknown diabetes diagnosed during ACS hospitalization, of HbA1c greater or equal to 8% at the time of admission, or newly introduced insulin therapy or severe/repeated hypoglycaemia. Referral to a diabetologist after hospital discharge is recommended if diabetes is diagnosed by the OGTT, or during cardiac rehabilitation in cases of uncontrolled diabetes (HbA1c ≥ 8%) or severe/repeated hypoglycaemia. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
